{Reference Type}: Case Reports
{Title}: Tenofovir-Induced Fanconi Syndrome Presenting with Life-Threatening Hypokalemia: Review of the Literature and Recommendations for Early Detection.
{Author}: Liatsou E;Tatouli I;Mpozikas A;Pavlou MM;Gakiopoulou H;Ntanasis-Stathopoulos I;Gavriatopoulou M;Kontogiannis S;Dimopoulos MA;
{Journal}: J Clin Med
{Volume}: 12
{Issue}: 22
{Year}: 2023 Nov 20
{Factor}: 4.964
{DOI}: 10.3390/jcm12227178
{Abstract}: Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor that has been widely used for the treatment of patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections. Despite the excellent safety records of this regimen, a few cases of acute renal failure and Fanconi syndrome have been reported among HIV patients exposed to TDF. However, in the HBV monoinfection scenario, only five cases of TDF-associated Fanconi syndrome have been reported thus far, two of them providing a confirmatory kidney biopsy. Here, we describe the case of a 68-year-old woman with chronic hepatitis B (CHB) who developed TDF-induced Fanconi syndrome that reverted after TDF withdrawal from tenofovir alafenamide. Though the overall risk of TDF-associated severe renal toxicity in HBV patients appears to be negligible, both glomerular and tubular functions should be monitored in patients exposed to TDF.